Induction Therapy Prior to Surgical Resection for Patients Presenting with Locally Advanced Esthesioneuroblastoma.
esthesioneuroblastoma
induction
neoadjuvant
outcomes
therapy
Journal
Journal of neurological surgery. Part B, Skull base
ISSN: 2193-6331
Titre abrégé: J Neurol Surg B Skull Base
Pays: Germany
ID NLM: 101580780
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
10
06
2019
accepted:
12
11
2019
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
ppublish
Résumé
Esthesioneuroblastoma (ENB) is a rare olfactory malignancy that can present with locally advanced disease. At our institution, patients with ENB in whom the treating surgeon believes that a margin-negative resection is initially not achievable are selected to undergo induction with chemotherapy with or without radiotherapy prior to surgery. In a retrospective review of 61 patient records, we identified six patients (10%) treated with this approach. Five of six patients (83%) went on to definitive surgery. Prior to surgery, three of five patients (60%) had a partial response after induction therapy, whereas two of five (40%) had stable disease. Microscopically margin-negative resection was achieved in four of five (80%) of the patients who went on to surgery, while one patient had negative margins on frozen section but microscopically positive margins on permanent section. Three of five patients (60%) recurred after surgery; two of these patients died with recurrent/metastatic ENB. In summary, induction therapy may facilitate margin-negative resection in locally advanced ENB. Given the apparent sensitivity of ENB to chemotherapy and radiotherapy, future prospective studies should investigate the optimal multidisciplinary approach to improve long-term survival in this rare disease.
Identifiants
pubmed: 34306928
doi: 10.1055/s-0039-3402026
pii: 190177
pmc: PMC8289526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e131-e137Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest A.V.C. reports funding for clinical trials from Merck, AstraZeneca/MedImmune, Kura Oncology, Inovio, Eisai (all institutional). The other authors report no relevant conflict of interest in submitting this article for publication.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Neurol Surg B Skull Base. 2012 Oct;73(5):331-6
pubmed: 24083125
Head Neck. 2005 Feb;27(2):138-49
pubmed: 15654688
Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8
pubmed: 9588546
Head Neck. 2019 May;41(5):1335-1341
pubmed: 30536472
J Pediatr Hematol Oncol. 2014 Mar;36(2):91-5
pubmed: 24390450
Cancer. 2008 Feb 15;112(4):885-91
pubmed: 18189294
J Clin Oncol. 2019 Feb 20;37(6):504-512
pubmed: 30615549
Laryngoscope. 1992 Aug;102(8):843-9
pubmed: 1495347
Lancet Oncol. 2001 Nov;2(11):683-90
pubmed: 11902539
Cancer. 2004 Nov 15;101(10):2257-60
pubmed: 15484215
J Neurol Surg B Skull Base. 2015 Feb;76(1):43-9
pubmed: 25685649
Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40
pubmed: 9006501
Neurosurgery. 1993 May;32(5):706-14; discussion 714-5
pubmed: 8492845
Oncotarget. 2016 Aug 9;7(32):52584-52596
pubmed: 27256979
J Neurol Surg B Skull Base. 2018 Oct;79(5):495-500
pubmed: 30210978
Cancer. 2002 May 15;94(10):2623-34
pubmed: 12173330
Cancer. 1994 May 15;73(10):2556-62
pubmed: 8174053
Anticancer Res. 1997 Jul-Aug;17(4A):2683-706
pubmed: 9252701
J Neurooncol. 2008 Nov;90(2):201-4
pubmed: 18633576
Int J Surg Oncol. 2016;2016:6923730
pubmed: 26955484
Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8
pubmed: 16490869
Acta Otolaryngol. 2003 Apr;123(3):433-9
pubmed: 12737303
Cancer Discov. 2019 Mar;9(3):354-369
pubmed: 30518523